日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

To generate functional anti-protease-activated receptor-4 (PAR4), a G protein-coupled receptor, antibodies through PAR4-mRNA-LNP immunization

为了生成功能性抗蛋白酶激活受体4 (PAR4)(一种G蛋白偶联受体)抗体,可通过PAR4-mRNA-LNP免疫接种实现。

Liu, En-Shuo; Ho, Kai-Wen; Wu, Chin-Chung; Fan, Hsiao-Li; Wang, Ting-Yu; Hsieh, Yuan-Chin; Huang, Bo-Cheng; Hong, Shih-Ting; Liao, Tzu-Yi; Liu, Yen-Ling; Chen, Yu-Tung; Lee, Chia-Ching; Chen, Chiao-Yun; Lin, Chih-Lung; Cheng, Tian-Lu

Spatial-hindrance-based pro-Adalimumab prevents anti-idiotypic antibody interference in pharmacokinetic and therapeutic efficacy.

基于空间阻碍的pro-Adalimumab可防止抗独特型抗体干扰药代动力学和治疗效果

Huang Bo-Cheng, Chen Yu-Tung, Lu Yun-Chi, Ho Kai-Wen, Hong Shih-Ting, Liao Tzu-Yi, Wu I-Hsuan, Liu En-Shuo, Liao Jun-Min, Chen Fang-Ming, Li Chia-Ching, Chuang Chih-Hung, Chen Chiao-Yun, Cheng Tian-Lu

Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery

用于靶向药物递送的抗体与聚乙二醇化纳米颗粒的非共价连接策略

Ho, Kai-Wen; Liu, Yen-Ling; Liao, Tzu-Yi; Liu, En-Shuo; Cheng, Tian-Lu

A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies.

一种用于开发人源化单克隆抗体的通用计算机模拟V(D)J重组策略

Hsieh Yuan-Chin, Liao Jun-Min, Chuang Kuo-Hsiang, Ho Kai-Wen, Hong Shih-Ting, Liu Hui-Ju, Huang Bo-Cheng, Chen I-Ju, Liu Yen-Ling, Wang Jaw-Yuan, Tsai Hsiang-Lin, Su Yu-Cheng, Wang Yen-Tseng, Cheng Tian-Lu

Fibrinogen-Like Protein 1 Serves as an Anti-Inflammatory Agent for Collagen-Induced Arthritis Therapy in Mice.

纤维蛋白原样蛋白 1 可作为抗炎剂用于治疗小鼠胶原蛋白诱导的关节炎

Lin Wen-Wei, Ho Kai-Wen, Su Hsiang-Han, Fang Tien-Fang, Tzou Shey-Cherng, Chen I-Ju, Lu Yun-Chi, Chang Mu-Shen, Tsai Yun-Chen, Liu En-Shuo, Su Yu-Cheng, Wang Yen-Tseng, Cheng Tian-Lu, Huang Hsin-Kai

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy.

选择性激活促抗IL-1β抗体可增强自身炎症性疾病治疗的特异性

Lin Wen-Wei, Lu Yun-Chi, Huang Bo-Cheng, Chuang Chih-Hung, Cheng Yi-An, Chen I-Ju, Liu Hui-Ju, Ho Kai-Wen, Liao Tzu-Yi, Liu En-Shuo, Wu Ting-Yi, Chang Long-Sen, Hong Shih-Ting, Cheng Tian-Lu